The average one-year price target for Rani Therapeutics Holdings (NasdaqGM:RANI) has been revised to $8.16 / share. This is a ...
Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical data ...
Welcome to the Rani Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are a in a listen-only mode. Following ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results